Objective: To assess the clinical and genetic characteristics of symptomatic children with hereditary hemorrhagic telangiectasia (HHT).
lated to pulmonary AVMs. Three had neurological symptoms secondary to bleeding from spinal or cerebral AVMs. Two were referred because of skin telangiectases and 2, because of multiple episodes of epistaxis. Screening results revealed a cerebral AVM in 1 of 11 neurologically asymptomatic children. Of the children without respiratory symptoms, 1 was diagnosed as having definite and 1, suspected pulmonary AVMs. Four children with pulmonary AVMs carried an endoglin gene mutation (HHT type 1), and 1 carried an activin receptor-like kinase 1 gene mutation (HHT type 2). The 2 children with spinal AVMs belong to the same HHT type 2 family. No mutation was found in 1 child with pulmonary and 1 with cerebral AVMs.
Conclusions: Visceral AVMs and mucosal telangiectases are present in children with HHT and can lead to life-threatening events. Failure to identify a diseaseassociated mutation for each child suggests complex mutations or novel HHT genes.
Arch Pediatr Adolesc Med. 2006; 160:596-601 H EREDITARY HEMORRHAGIC telangiectasia (HHT), or Rendu-Osler-Weber syndrome, is an autosomal dominant vascular dysplasia. Although initially thought to be rare, recent reports suggest a prevalence of 1:5000 to 1:10 000. 1, 2 Hereditary hemorrhagic telangiectasia is characterized by mucocutaneous telangiectatic lesions, resulting in epistaxis in 90% of patients 3 and gastrointestinal tract bleeding in 20% to 30%. 4 Visceral arteriovenous malformations (AVMs) are predominantly found in the pulmonary, cerebral, and hepatic circulations. 5, 6 The clinical characteristics of HHT in children are not well described. Symptoms and signs tend to develop in late childhood and early adulthood, 2, 5, 6 and many children do not experience epistaxis or develop skin telangiectases in the first decade of life. 6 Multiple reports 7-12 of cerebral and pulmonary AVMs in children have been published; however, prevalence of such AVMs has not been established, and there are no published series describing the clinical presentations and genetics of HHT in childhood.
We aimed to characterize the clinical presentation, presence of asymptomatic visceral AVMs, and genotype in children symptomatic for HHT.
1996, through December 31, 2002, were included in the current study. Children referred because of a family history and found to have HHT were not included.
The children were examined carefully for skin and mucosal telangiectases. Thorough examinations of the oral and conjunctival mucous membranes and anterior rhinoscopy for nasal telangiectases were also performed.
The children were screened for visceral AVMs. Pulmonary AVMs were diagnosed by means of echocardiography with agitated saline contrast and enhanced chest computed tomography followed by pulmonary angiography when indicated. Cerebral AVMs were diagnosed by means of head magnetic resonance imaging, followed by cerebral angiography when indicated.
Clinical diagnosis of HHT was based on the established clinical diagnostic criteria for HHT. These criteria include recurrent epistaxis, multiple skin telangiectases, visceral AVMs or telangiectases, and a first-degree family member with HHT. 13 Having 3 criteria confirms the diagnosis, whereas having 2 criteria leads to a diagnosis of suspected HHT. 
RESULTS
We examined 127 children in the Toronto HHT clinics from April 1, 1996, through December 31, 2002. One hundred thirteen were referred because of a family history of HHT, and 14 (age range, 0-15 years; median age, 9 years) because of symptoms or signs of HHT. This report describes these 14 children. Their clinical presentation, disease characteristics, and results of molecular analysis are summarized in the Table. Nine (64%) had a family history of HHT, and mutations were found in 8.
Seven children (50%) presented with pulmonary AVMs; 3 (21%), with cerebral or spinal AVMs; and 4 (29%), with mucocutaneous telangiectases. Epistaxis was common, being observed in 12 children (86%), but usually mild; severe nosebleeds were described in only 3 children.
CLINICAL PRESENTATION OF PULMONARY AVMs
Of the 7 children with pulmonary AVMs, 5 had a prolonged history of dyspnea and cyanosis that started years before the diagnosis, 1 presented with congestive heart failure, and 1 presented with hemoptysis. The pulmonary presentation and outcome of patients 1 through 5, 7, and 10 were reported in a large series summarizing the outcome of transcatheter embolotherapy for pulmonary AVMs 18 and diffuse pulmonary AVMs. 19 However, complete screening for other AVMs and HHT mutation analysis were not described previously. Patient 1 was diagnosed at 11 months of age as having lactic acidosis and mitochondrial myopathy, probably unrelated to HHT. The diagnosis of HHT was established 3 years later, after referral because of epistaxis, dyspnea, and cyanosis. A large pulmonary AVM was found in the left lower lobe and required embolization. After 5 years of follow-up, the child is well, with no evidence of pulmonary AVMs. This child was the first in the family to show signs of HHT. Molecular analysis revealed an ENG splice-site mutation (g.IVS3ϩ1GϾA), which leads to an exon 3 skip and expression of an in-frame smaller and unstable ENGmutant protein. The child's asymptomatic mother was subsequently shown to have pulmonary and hepatic AVMs. She had passed on the mutation to her child but had not inherited it from her parents, who did not carry the mutation and showed no signs of HHT. Results of DNA fingerprinting with 8 different markers confirmed that the child and his mother share the expected alleles with their respective parents. 15 This mutation was thus occurring de novo in the mother. This same splice-site variant has also been reported in an unrelated family with several generations of HHT, 20 confirming that the same mutation can arise in distinct families.
Patient 2 had a very complicated course characterized by multiple-organ involvement. She was diagnosed in early childhood as having hypothyroidism and developmental delay. She was noted to have long-standing cyanosis and multiple mucocutaneous telangiectases. However, the diagnosis of HHT was only established at 12 years of age, when she manifested diffuse pulmonary AVMs and an occipital cerebral AVM. She also had liver disease, with elevated transaminase levels and with coagulopathy that remained enigmatic even after a liver biopsy. Transcatheter embolotherapies resulted in only transient improvement. Lung transplantation was offered but refused. Epistaxis appeared at 17 years of age. The patient continued to have severe cyanosis and died at 18 years of age. A novel ENG exon 5 substitution (c.640GϾA), which converts glycine to serine at codon 214, was identified. The patient did not have a family history of HHT. The same sequence variant was found in her asymptomatic mother and is likely disease associated because it was not identified in more than 200 individuals who underwent testing. However, confirmation of this sequence variant as disease associated requires further study.
Patient 3 presented at 7 years of age with multiple telangiectases and prolonged cyanosis. During 13 years of follow-up, multiple pulmonary AVMs were embolized on 3 occasions (Figure, second embolotherapy) , with symptomatic improvement and resolution of hypoxemia. A previously unreported ENG mutation was found in the patient and 2 affected relatives: a 4-base insertion c.982_983insGCCT in exon 7, which causes a frame shift.
Patients 4 and 5 presented with severe cyanosis. Diffuse pulmonary AVMs required multiple transcatheter embolizations (and right lower lobectomy in patient 4), with only transient improvement.
Patient 6 presented with severe respiratory distress soon after birth. A large pulmonary AVM, causing congestive heart failure, was found in the left upper lobe, and lo-bectomy was performed. After 14 years of follow-up, except for a few cutaneous telangiectases that appeared during follow-up, she is asymptomatic with no evidence of pulmonary AVMs. A missense mutation in exon 4 of ACVRL1 (c.383CϾA), which changes alanine to aspartic acid at codon 128, was found in this child and her affected parent. 21 Patient 7 presented at 11 years of age with recurrent hemoptysis. Chest imaging revealed multiple pulmonary AVMs, which were embolized with significant improvement. Recurrent hemoptysis due to laryngeal and tracheal telangiectases responded well to laser ablation. Six years later, she required transcatheter embolotherapy of bilateral pulmonary AVMs causing hypoxia, with resolution of symptoms. Skin telangiectases were noticed at 15 years of age. A duplication of ENG exons 3 through 8 was found in this patient and her affected parent, and a large unstable intracellular protein could be observed, as previously reported for an unrelated family.
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CLINICAL PRESENTATION OF CEREBRAL AND SPINAL AVMs
Three children presented with neurological symptoms. Patients 8 and 9, first cousins, were diagnosed as having spinal AVMs, and their initial course was described elsewhere. 22 Patient 8 experienced new neurological symptoms 3 years after the feeding artery to the AVM was ligated. A new spinal AVM was found and embolized. These 2 children belong to the same family with HHT2, characterized by an ACVRL1 missense mutation (c.1232GϾA), which converts arginine to glutamine at codon 411, and was reported as a disease-causing mutation in seemingly unrelated families. Patient 10 presented with right hemiparesis, headache, and seizures. Two cerebral AVMs were found and embolized. Complete sequencing of ENG and ACVRL1 genes failed to identify a mutation in her clinically affected relatives.
All 3 patients required rehabilitation, with resolution of most symptoms.
MUCOCUTANEOUS TELANGIECTASES AND EPISTAXIS
Only 4 children were referred because of mucocutaneous telangiectases and epistaxis; however, all children presented with mucocutaneous telangiectases and/or epistaxis during follow-up. Epistaxis appeared as early as 3 years of age (mean±SD age of first episode, 7.5±4.0 years). Patient 11 was referred because of multiple skin telangiectases, epistaxis, and an episode of a transient ischemic attack, with no family history of HHT. Results of a physical examination revealed multiple skin telangiectases on her palms and nasal mucosa. Echocardiography with agitated saline injection and chest computed tomography failed to demonstrate pulmonary AVMs. Pulmonary angiography was not performed because the probability of finding an AVM large enough to be embolized was very low. Head magnetic resonance imaging did not display any ischemic or hemorrhagic changes. No cerebral AVMs were seen. The cause of the transient ischemic attack could not be determined, and migraine remains a probable diagnosis. However, the presence of minute pulmonary AVMs cannot be ruled out. Molecular analysis failed to reveal a mutation in the ENG or the ACVRL1 gene.
Patient 12 presented with multiple telangiectases on his face and extremities and epistaxis that started at 3 years of age and tended to be frequent (up to few times a week) and difficult to control (each episode lasting up to 1 hour). However, epistaxis was not treated before referral to our clinic. Patients 13 and 14 presented with epistaxis and were both treated successfully with cauterization or laser ablation. Patient 14 was found to carry the previously reported familial ACVRL1 missense mutation (c.1232GϾA) and is unrelated to patients 8 and 9.
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ASYMPTOMATIC AVMs DETECTED ON SCREENING
Thirteen children were screened for pulmonary and cerebral AVMs. Of the 11 neurologically asymptomatic children, patient 2 was found to have a cerebral AVM. Of the children with no respiratory symptoms, patient 10 was found to have pulmonary AVMs and underwent transcatheter embolotherapy. Patient 14, with genetically proven HHT2, had echocardiographic and computed tomographic findings suggestive of small pulmonary AVMs. He is being followed up conservatively.
CLINICAL DIAGNOSTIC CRITERIA FOR HHT
Eleven of the 14 children currently meet the established diagnostic criteria for definite HHT. However, because epistaxis or telangiectases appeared in 5 children after their first presentation, 4 of them did not meet these criteria at presentation. As of this writing, 3 children still did not have sufficient criteria for a definite diagnosis of HHT. The transient ischemic attack in patient 11 raises a major concern that she has pulmonary AVMs; however, extensive workup failed to demonstrate any. Thus, according to the diagnostic criteria, she is suspected of having HHT. Patients 12 and 13 have telangiectases and severe epistaxis with no evidence of visceral AVMs and no family history of HHT. However, telangiectases and/or epistaxis exist in these families, and screening for visceral AVMs was not performed in family members.
COMMENT
A pediatric HHT clinic was established in Toronto for treating children with HHT. In a recent series 24 describing 15 children with HHT, epistaxis was common, appearing as early as 4 years of age. However, symptoms of visceral AVMs were rare, and screening for visceral AVMs was performed in only 6 children.
Five of the symptomatic children in our series presented with acute life-threatening events, including stroke, hemoptysis, and congestive heart failure. Five presented with chronic hypoxia. Previous reports 2,25-28 have established the prevalence of cerebral and pulmonary AVMs at 5% to 10% and 15% to 33%, respectively, in adults with HHT. Much less attention has been given to children with this disease. It was also shown that most pulmonary AVMs grow during life, 26 but it is not known whether all pulmonary AVMs are present at birth or some develop later. Multiple cases of fatal complications of cerebral AVMs have been reported in children with HHT. 7, [10] [11] [12] We examined 127 children, 113 of them because of a family history and 14 because of symptoms. Ten children presented with symptomatic visceral AVMs. 
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